Boston Scientific Corporation (BSX)

Over the past six months, Boston Scientific's stock (BSX) has experienced a notable decline. The stock was down approximately 13.79% over the past 30 days and a significant 47.79% over the past 12 months, with a 52-week range between $53.63 and $109.50. Recent events impacting the stock include Q1 CY2026 earnings exceeding market revenue expectations but with lowered Q2 CY2026 revenue guidance and full-year adjusted EPS guidance, multiple securities class action lawsuits alleging misleading statements about the growth in the U.S. electrophysiology business, and strong Q3 2025 results with net sales of $5.065 billion and adjusted EPS of $0.75.

While specific detailed patterns of demand seasonality for Boston Scientific's products and services are not extensively elaborated, there are indications that seasonality exists. Analyst consensus suggests a "high end of typical seasonality" for sequential quarterly earnings growth. Platforms that analyze stock performance offer tools to identify seasonal patterns for BSX, implying that historical data reveals recurring trends in demand or stock performance throughout the year.

Boston Scientific Corporation (BSX) is a global medical device company focused on less-invasive medical technologies, operating within the healthcare sector. The company designs, manufactures, and markets a broad portfolio of medical devices used in various interventional medical specialties, including drug-eluting stents, cardiac rhythm management devices, and endoscopy products. The company is known for developing products like the Taxus Stent and the EMBLEM subcutaneous implantable defibrillator (S-ICD).

Boston Scientific has a significant global presence, operating in approximately 125 countries. The company's operations are primarily divided into U.S. and International regions. Its global corporate headquarters are in Marlborough, Massachusetts, USA, with regional headquarters in Singapore and Paris. Major technology centers are located in Minnesota, California, Ireland, and Costa Rica, and the company maintains 13 manufacturing facilities globally. In fiscal year 2025, the United States represented the largest portion of its revenue, accounting for 64.08% of total revenue, while non-U.S. regions contributed 35.92%.

In the past year, Boston Scientific's brand reputation has been impacted by legal challenges. Multiple securities class action lawsuits have been filed against the company alleging that management made misleading statements regarding the growth trajectory and competitive positioning of its U.S. electrophysiology business, particularly after weaker sales in Q4 2025 and a subsequent soft guidance for 2026.

Boston Scientific's ownership is predominantly institutional, with 1721 institutional owners and shareholders holding a total of 1,488,405,393 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Fmr Llc (Fidelity Management & Research), State Street Corp, Geode Capital Management, Llc, Primecap Management Co/ca/, Capital World Investors, and Jpmorgan Chase & Co. Institutional investors collectively own approximately 50.99% to over 70% of the company's stock, while insiders hold a low single-digit percentage (around 0.16%).